Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
Open Access
- 12 October 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (10) , e2236298
Abstract
The COVID-19 pandemic had widespread impacts on health care delivery. Concerns that COVID-19 would disrupt access to potentially lifesaving treatment for people with opioid use disorder (OUD) prompted abrupt federal policy changes in March 2020 to allow increased telehealth delivery of buprenorphine,1 a first-line OUD treatment that is known to prevent overdose death and can be prescribed in office-based settings.2,3 These changes included eliminating the required initial in-person visit before a patient could be transitioned to telehealth under the public health emergency exception of the Ryan Haight Online Pharmacy Consumer Protection Act.4 Additionally, updated guidance from the Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA) allowed—for the first time—buprenorphine visits for new and existing patients to be delivered by telephone (ie, audio-only).5 Policy makers and health care leaders are currently debating whether to maintain or roll back policies that have increased flexibility in buprenorphine delivery.6 To inform these decisions, it is important to understand the potential relationship of buprenorphine treatment modality (video, telephone, or in-person) with treatment outcomes, as well as the characteristics of patients who are more or less likely to access different modalities.Keywords
This publication has 48 references indexed in Scilit:
- Prevention and Treatment of Opioid Misuse and AddictionJAMA Psychiatry, 2019
- Medications for Opioid Use Disorder in the Department of Veterans Affairs (Va) Health Care System: Historical Perspective, Lessons Learned, and Next StepsSubstance Abuse, 2018
- Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health AdministrationDrug and Alcohol Dependence, 2016
- Impact of treatment for opioid dependence on fatal drug‐related poisoning: a national cohort study in EnglandAddiction, 2015
- A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative DataMedical Care, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesAnnals of Internal Medicine, 2007
- The influence of distance on utilization of outpatient mental health aftercare following inpatient substance abuse treatmentAddictive Behaviors, 2003
- Racial Differences in Diabetic Nephropathy, Cardiovascular Disease, and Mortality in a National Population of VeteransDiabetes Care, 2003
- Statistical Analysis of Correlated Data Using Generalized Estimating Equations: An OrientationAmerican Journal of Epidemiology, 2003
- Longitudinal Data Analysis for Discrete and Continuous OutcomesBiometrics, 1986